Drug intelligence / Profile preview

(5e,13e)-11-hydroxy-9,15-dioxoprosta-5,13-dien-1-oic acid

Development stage: Unknown
Modality: Small Molecules

Overview

(5E,13E)-11-Hydroxy-9,15-dioxoprosta-5,13-dien-1-oic acid is a small molecule with experimental status. It is not approved for any indication and has not been developed as a pharmaceutical product. The compound is involved in the metabolic inactivation of pro-inflammatory and anti-inflammatory eicosanoids through NAD(P)H-dependent oxidoreductase activity[1]. No specific developer or manufacturer information is available.

Other names: (5E,13E)-11-HYDROXY-9,15-DIOXOPROSTA-5,13-DIEN-1-OIC ACID

Targets

PTGR1 (Prostaglandin reductase 1)

Beyond the preview

Go deeper on (5e,13e)-11-hydroxy-9,15-dioxoprosta-5,13-dien-1-oic acid.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on (5e,13e)-11-hydroxy-9,15-dioxoprosta-5,13-dien-1-oic acid.

Explore the full profile